Score Overview
United Therapeutics Corporation fundamental performance
Between 2020 and 2025, revenue grew from $ 1.48B to $ 3.18B and net income grew from $ 514M to $ 1.33B. Revenue increased in 4 of those 5 years; net income in 4.
Across United Therapeutics Corporation's full reported history, from 1999 to 2025, revenue grew from $ 400K to $ 3.18B and net income went from -$ 33M to $ 1.33B. Revenue increased in 89% of the years measured; net income in 70%.
United Therapeutics Corporation currently holds a 20-year HDB Score of 7.6 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 511.72 | — |
1 Year2025-08-12 | $ 301.39 | 69.79% |
5 Years2021-08-12 | $ 203.05 | 152.02% |
10 Years2016-08-12 | $ 125.19 | 308.75% |
20 Years2006-08-11 | $ 27.14 | 18x |
All Time1999-06-17 | $ 6.09 | 83x |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | 10 Years2016-08-12 | 20 Years2006-08-11 | All Time1999-06-17 |
|---|---|---|---|---|---|---|
| Price | $ 511.72 | $ 301.39 | $ 203.05 | $ 125.19 | $ 27.14 | $ 6.09 |
| Return | — | 69.79% | 152.02% | 308.75% | 18x | 83x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 3.15B | $ 1.31B | $ 2.66B |
| 2025 | $ 3.18B | $ 1.33B | $ 1.55B |
| 2024 | $ 2.87B | $ 1.19B | $ 3.26B |
| 2023 | $ 2.32B | $ 984M | $ 2.99B |
| 2022 | $ 1.93B | $ 727M | $ 2.83B |
| 2021 | $ 1.68B | $ 475M | $ 1.93B |
| 2020 | $ 1.48B | $ 514M | $ 1.83B |
| 2019 | $ 1.44B | -$ 104M | $ 1.48B |
| 2018 | $ 1.62B | $ 589M | $ 1.41B |
| 2017 | $ 1.72B | $ 417M | $ 1.43B |
| 2016 | $ 1.59B | $ 713M | $ 1.05B |
| 2015 | $ 1.46B | $ 651M | $ 953M |
| 2014 | $ 1.28B | $ 340M | $ 695M |
| 2013 | $ 1.11B | $ 174M | $ 693M |
| 2012 | $ 916M | $ 304M | $ 479M |
| 2011 | $ 743M | $ 217M | $ 403M |
| 2010 | $ 603M | $ 105M | $ 627M |
| 2009 | $ 369M | $ 19M | $ 229M |
| 2008 | $ 281M | -$ 42M | $ 236M |
| 2007 | $ 210M | $ 19M | $ 290M |
| 2006 | $ 159M | $ 73M | $ 227M |
| 2005 | $ 115M | $ 65M | $ 125M |
| 2004 | $ 73M | $ 15M | $ 82M |
| 2003 | $ 53M | -$ 9M | $ 68M |
| 2002 | $ 30M | -$ 23M | $ 122M |
| 2001 | $ 5M | -$ 37M | $ 56M |
| 2000 | $ 2M | -$ 75M | $ 215M |
| IPO1999 | $ 400K | -$ 33M | $ 51M |
Explore beyond UTHR
You're looking at United Therapeutics Corporation. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
